Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | SCN4A | P35499 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10220117 | 0.83 | HSD17B10 (0.39) | ALDH1A1RAB9ASMN1; SMN2NPC1TLR8 | |
| SCHEMBL20667373 | 0.83 | ALDH1A1 (0.39) | ALDH1A1RAB9ASMN1; SMN2NPC1SCN4A | |
| SCHEMBL20666431 | 0.81 | ALDH1A1 (0.62) | ALDH1A1RAB9ASMN1; SMN2NPC1SCN4A | |
| SCHEMBL21160893 | 0.79 | RAB9A (0.36) | ALDH1A1RAB9ASMN1; SMN2NPC1SCN4A | |
| SCHEMBL23502557 | 0.79 | GABRA1 (0.39) | ALDH1A1RAB9ASMN1; SMN2NPC1SCN4A | |
| SCHEMBL20049394 | 0.79 | ALDH1A1 (0.36) | ALDH1A1RAB9ASMN1; SMN2NPC1SCN4A | |
| SCHEMBL20047402 | 0.79 | ALDH1A1 (0.36) | ALDH1A1RAB9ASMN1; SMN2NPC1TLR8 | |
| SCHEMBL20666434 | 0.79 | ALDH1A1 (0.36) | ALDH1A1RAB9ASMN1; SMN2NPC1TLR8 | |
| SCHEMBL20666438 | 0.78 | ALDH1A1 (0.35) | ALDH1A1RAB9ASMN1; SMN2NPC1SCN4A | |
| SCHEMBL21098148 | 0.77 | ALDH1A1 (0.34) | ALDH1A1RAB9ASMN1; SMN2NPC1SCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | NUVATION BIO INC (US) | 2021-09-23 | — | — | US | disclosed |
| US-20200231570-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2020-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200231570-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | ALDH1A1 2100/4885RAB9A 2816/4885SMN1; SMN2 4476/4885 |
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | ALDH1A1 2100/4885RAB9A 2816/4885SMN1; SMN2 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.